DOCSLIB.ORG

Epithelial Tissues Expressed in the Central Nervous System And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CSMD1 Is a Novel Multiple Domain Complement-Regulatory Protein Highly Expressed in the Central Nervous System and Epithelial Tissues This information is current as of September 25, 2021. Damian M. Kraus, Gary S. Elliott, Hilary Chute, Thomas Horan, Karl H. Pfenninger, Staci D. Sanford, Stephen Foster, Sheila Scully, Andrew A. Welcher and V. Michael Holers J Immunol 2006; 176:4419-4430; ; doi: 10.4049/jimmunol.176.7.4419 Downloaded from http://www.jimmunol.org/content/176/7/4419 References This article cites 50 articles, 23 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/176/7/4419.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 25, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology CSMD1 Is a Novel Multiple Domain Complement-Regulatory Protein Highly Expressed in the Central Nervous System and Epithelial Tissues1 Damian M. Kraus,* Gary S. Elliott,† Hilary Chute,† Thomas Horan,† Karl H. Pfenninger,‡ Staci D. Sanford,‡ Stephen Foster,† Sheila Scully,† Andrew A. Welcher,† and V. Michael Holers2* In this study, we describe the identification and in vitro functional activity of a novel multiple domain complement regulatory protein discovered based on its homology to short consensus repeat (SCR)-containing proteins of the regulators of complement activation (RCA) gene family. The rat cDNA encodes a predicted 388-kDa protein consisting of 14 N-terminal CUB domains that are separated from each other by a SCR followed by 15 tandem SCR domains, a transmembrane domain, and a short cytoplasmic Downloaded from tail. This protein is the homolog of the human protein of unknown function called the CUB and sushi multiple domains 1 (CSMD1) protein. A cloning strategy that incorporates the two C-terminal CUB-SCR domains and 12 of the tandem SCR repeats was used to produce a soluble rat CSMD1 protein. This protein blocked classical complement pathway activation in a comparable fashion with rat Crry but did not block alternative pathway activation. Analysis of CSMD1 mRNA expression by in situ hybridization and immunolabeling of neurons indicates that the primary sites of synthesis are the developing CNS and epithelial tissues. Of par- ticular significance is the enrichment of CSMD1 in the nerve growth cone, the amoeboid-leading edge of the growing neuron. These http://www.jimmunol.org/ results suggest that CSMD1 may be an important regulator of complement activation and inflammation in the developing CNS, and that it may also play a role in the context of growth cone function. The Journal of Immunology, 2006, 176: 4419–4430. he complement system consists of over 30 fluid phase and In addition to a protective role, activation of the complement cell membrane proteins that act independently or in con- pathway can also exacerbate inflammatory injury and cause exten- T cert to defend against invading pathogens. Foreign sub- sive damage to self-tissues. To avoid or reduce inadvertent injury, strates activate complement via the classical pathway involving C1 host cells are protected by complement regulatory molecules (C1q, C1r, C1s), C4, C2, and C3 or the alternative pathway in- present in the fluid phase and on cell membranes that inhibit both by guest on September 25, 2021 volving C3, factor B, factor D, and properdin (1, 2). These proteins classical and alternative pathway activation pathways at several form C3 convertases, C4bC2a of the classical pathway or C3bBb points in the cascade. The largest group of proteins responsible for of the alternative pathway, which cleave C3 to C3b. Bound C3b controlling the actions of complement are encoded by closely serves as a covalently attached opsonin that can be cleaved by linked genes present in a locus on chromosome 1 designated the factor I to generate additional C3 fragments. Opsonization by C3b regulators of complement activation (RCA3; Ref. 4). RCA genes fragments is required for recognition of pathogens and foreign Ags encode the soluble regulatory proteins factor H and C4b-binding by appropriate cell types and initiation of cellular processes that protein, as well as the membrane-bound proteins decay-accelerat- remove immune complexes and enhance the humoral immune re- ing factor, membrane cofactor protein, and murine Crry. Regula- sponse. Substrate-bound C3b molecules also serve as focal points tion of complement is achieved by dissociation of C3 and C5 con- for the formation of additional C3 convertases in addition to the C5 vertases or by binding to and inactivating C3b through factor I convertases, C4bC2aC3b of the classical pathway and C3bBbC3b proteolytic activity. of the alternative pathway. Once C5 convertases are formed, target Foreign Ags opsonized with complement allow host inflamma- organisms can be lysed following cleavage of C5 to C5b and as- tory cells and erythrocytes to bind immune complexes via the cell sembly of complement components C6, C7, C8, and C9 to gener- surface RCA complement receptors, CR1 and CR2 (5). CR1 binds ate the lytic membrane attack complex (3). activation fragments of C3, which facilitates the recognition and removal of immune complexes from the circulation and also can serve as a regulatory protein (6–8). CR1 has limited tissue distri- bution and is expressed on erythrocytes, phagocytic cells, T and B *Division of Rheumatology, University of Colorado Health Sciences Center, Denver, CO 80262; †Amgen, Thousand Oaks, CA 91320; and ‡Departments of Pediatrics and lymphocytes, and follicular dendritic cells. CR2 binds iC3b/C3d of Cell and Developmental Biology, University of Colorado Health Sciences Center, opsonized immune complexes (9) and also serves as a receptor for Aurora, CO 80045 EBV (10, 11). CR2 is expressed primarily on B lymphocytes and Received for publication July 25, 2005. Accepted for publication January 17, 2006. follicular dendritic cells where it serves as a link between the in- The costs of publication of this article were defrayed in part by the payment of page nate and acquired immune systems by enhancing induction of the charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by National Institutes of Health Grants R01 AI31105 (to 3 Abbreviations used in this paper: RCA, regulator of complement activation; CR, V.M.H.), R01 NS041029 (to K.H.P.), and by collaboration from Amgen. complement receptor; SCR, short consensus repeat; CSMD1, CUB-sushi multiple 2 Address correspondence and reprint requests to Dr. V. Michael Holers, Division of domain 1; EST, expressed sequence tag; rs, recombinant soluble; PSG, penicillin/ Rheumatology, University of Colorado Health Sciences Center, B-115, 4200 East 9th streptomycin/glutamine; EA, Ab-sensitized sheep erythrocyte; AD, Alzheimer’s dis- Avenue, Denver, CO 80262. E-mail address: [email protected] ease; MASP, mannose-binding lectin-associated serine protease. Copyright © 2006 by The American Association of Immunologists, Inc. 0022-1767/06/$02.00 4420 NOVEL MULTIPLE DOMAIN COMPLEMENT REGULATOR humoral immune response and the maintenance of immunological Table I. 5Ј RACE primers memory (12–16). Despite functional differences, the RCA proteins are homologs No. Primer Sequence and Designation of each other, each being composed of a tandem array of the ϳ 1 8949-GGTGCCAGGGTTTCCACAGGAC-8928 60-aa structural motif designated short consensus repeat (SCR; 2 8915-ACAGGCTGGACTCCTGACCAGG-8894 also known as sushi repeat or complement control module) (4, 17). 3 8007-GCTCCAGAGACCATTGGCCAAGC-7985 SCR domains have a multiple ␤-strand structure held together, in 4 7981-CCCGGACATGGGAGCCTACAAG-7959 part, by four conserved cysteine (Cys) residues that form disulfide 5 6206-GAGTGGTCACTATAGAAGCGGATG-5183 6178-TTTCATGTGTGGTGCTCAGCAGTG-6155 bonds between Cys 1 and Cys 3 and between Cys 2 and Cys 4. 6 7 5226-GCTGCACTGCGTGTCACTGGTG-5205 Unlike most extracellular proteins that have more than one type of 8 5197-CGGCTTGGTAGACGAAGTGGAAAC-5174 structural domain, each type being defined by a specific consensus 9 4820-CCTGTCACACACTCAATGGATGAG-4797 sequence, the RCA proteins do not contain any of the other widely 10 4786-TCTTGTAACCAGAGTCACATTGATAG-4761 occurring module types. Furthermore, no other domain besides the 11 4450-TCACCTTAATTCTCCAGTCACACTC-4426 12 4281-GGCTTGCCCTTGGAGCTGGTATC-4258 SCR has been identified in proteins with the capacity to regulate 13 3827-TCCGCCACACAGGAAGGCATAGG-3805 complement activation at the C3 and C5 convertase steps. Decay- 14 3717-CACAGTGTCTGTGAAGTGACCATC-3694 accelerating factor and membrane cofactor protein are each com- 15 3868-GTATGCGTCCTGATGTGGCTGC-3846 posed of 4 SCRs, the murine regulator Crry has 5 SCRs, factor H 16 3840-GAGACCACCACATTCCGCCACA-3819
Recommended publications
  • Metastatic Adrenocortical Carcinoma Displays Higher Mutation Rate and Tumor Heterogeneity Than Primary Tumors

    Metastatic Adrenocortical Carcinoma Displays Higher Mutation Rate and Tumor Heterogeneity Than Primary Tumors

    ARTICLE DOI: 10.1038/s41467-018-06366-z OPEN Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors Sudheer Kumar Gara1, Justin Lack2, Lisa Zhang1, Emerson Harris1, Margaret Cam2 & Electron Kebebew1,3 Adrenocortical cancer (ACC) is a rare cancer with poor prognosis and high mortality due to metastatic disease. All reported genetic alterations have been in primary ACC, and it is 1234567890():,; unknown if there is molecular heterogeneity in ACC. Here, we report the genetic changes associated with metastatic ACC compared to primary ACCs and tumor heterogeneity. We performed whole-exome sequencing of 33 metastatic tumors. The overall mutation rate (per megabase) in metastatic tumors was 2.8-fold higher than primary ACC tumor samples. We found tumor heterogeneity among different metastatic sites in ACC and discovered recurrent mutations in several novel genes. We observed 37–57% overlap in genes that are mutated among different metastatic sites within the same patient. We also identified new therapeutic targets in recurrent and metastatic ACC not previously described in primary ACCs. 1 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 2 Center for Cancer Research, Collaborative Bioinformatics Resource, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. 3 Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Correspondence and requests for materials should be addressed to E.K. (email: [email protected]) NATURE COMMUNICATIONS | (2018) 9:4172 | DOI: 10.1038/s41467-018-06366-z | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06366-z drenocortical carcinoma (ACC) is a rare malignancy with types including primary ACC from the TCGA to understand our A0.7–2 cases per million per year1,2.
  • (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation

    (P -Value<0.05, Fold Change≥1.4), 4 Vs. 0 Gy Irradiation

    Table S1: Significant differentially expressed genes (P -Value<0.05, Fold Change≥1.4), 4 vs. 0 Gy irradiation Genbank Fold Change P -Value Gene Symbol Description Accession Q9F8M7_CARHY (Q9F8M7) DTDP-glucose 4,6-dehydratase (Fragment), partial (9%) 6.70 0.017399678 THC2699065 [THC2719287] 5.53 0.003379195 BC013657 BC013657 Homo sapiens cDNA clone IMAGE:4152983, partial cds. [BC013657] 5.10 0.024641735 THC2750781 Ciliary dynein heavy chain 5 (Axonemal beta dynein heavy chain 5) (HL1). 4.07 0.04353262 DNAH5 [Source:Uniprot/SWISSPROT;Acc:Q8TE73] [ENST00000382416] 3.81 0.002855909 NM_145263 SPATA18 Homo sapiens spermatogenesis associated 18 homolog (rat) (SPATA18), mRNA [NM_145263] AA418814 zw01a02.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:767978 3', 3.69 0.03203913 AA418814 AA418814 mRNA sequence [AA418814] AL356953 leucine-rich repeat-containing G protein-coupled receptor 6 {Homo sapiens} (exp=0; 3.63 0.0277936 THC2705989 wgp=1; cg=0), partial (4%) [THC2752981] AA484677 ne64a07.s1 NCI_CGAP_Alv1 Homo sapiens cDNA clone IMAGE:909012, mRNA 3.63 0.027098073 AA484677 AA484677 sequence [AA484677] oe06h09.s1 NCI_CGAP_Ov2 Homo sapiens cDNA clone IMAGE:1385153, mRNA sequence 3.48 0.04468495 AA837799 AA837799 [AA837799] Homo sapiens hypothetical protein LOC340109, mRNA (cDNA clone IMAGE:5578073), partial 3.27 0.031178378 BC039509 LOC643401 cds. [BC039509] Homo sapiens Fas (TNF receptor superfamily, member 6) (FAS), transcript variant 1, mRNA 3.24 0.022156298 NM_000043 FAS [NM_000043] 3.20 0.021043295 A_32_P125056 BF803942 CM2-CI0135-021100-477-g08 CI0135 Homo sapiens cDNA, mRNA sequence 3.04 0.043389246 BF803942 BF803942 [BF803942] 3.03 0.002430239 NM_015920 RPS27L Homo sapiens ribosomal protein S27-like (RPS27L), mRNA [NM_015920] Homo sapiens tumor necrosis factor receptor superfamily, member 10c, decoy without an 2.98 0.021202829 NM_003841 TNFRSF10C intracellular domain (TNFRSF10C), mRNA [NM_003841] 2.97 0.03243901 AB002384 C6orf32 Homo sapiens mRNA for KIAA0386 gene, partial cds.
  • Whole-Exome Sequencing Associates Novel CSMD1 Gene Mutations with Familial Parkinson Disease

    Whole-Exome Sequencing Associates Novel CSMD1 Gene Mutations with Familial Parkinson Disease

    Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson disease Javier Ruiz-Martínez, ABSTRACT MD, PhD Objective: Despite the enormous advancements made in deciphering the genetic architecture of Luis J. Azcona, BBA Parkinson disease (PD), the majority of PD is idiopathic, with single gene mutations explaining only Alberto Bergareche, MD a small proportion of the cases. Jose F. Martí-Massó, MD, Methods: In this study, we clinically evaluated 2 unrelated Spanish families diagnosed with PD, in PhD which known PD genes were previously excluded, and performed whole-exome sequencing anal- Coro Paisán-Ruiz, PhD yses in affected individuals for disease gene identification. Results: Patients were diagnosed with typical PD without relevant distinctive symptoms. Two dif- Correspondence to ferent novel mutations were identified in the CSMD1 gene. The CSMD1 gene, which encodes Dr. Paisán-Ruiz: a complement control protein that is known to participate in the complement activation and [email protected] inflammation in the developing CNS, was previously shown to be associated with the risk of PD in a genome-wide association study. Conclusions: We conclude that the CSMD1 mutations identified in this study might be responsible for the PD phenotype observed in our examined patients. This, along with previous reported studies, may suggest the complement pathway as an important therapeutic target for PD and other neurodegenerative diseases. Neurol Genet 2017;3:e177; doi: 10.1212/NXG.0000000000000177 GLOSSARY AD 5 Alzheimer disease; CCP 5 complement control protein; fPD 5 familial Parkinson disease; H&Y 5 Hoehn and Yahr; INDEL 5 insertions/deletions; LOPD 5 late-onset PD; PD 5 Parkinson disease; RBD 5 REM sleep behavior disorder; RLS 5 restless legs syndrome; SNV 5 single nucleotide variant; WES 5 whole-exome sequencing.
  • Mechanisms Underlying Phenotypic Heterogeneity in Simplex Autism Spectrum Disorders

    Mechanisms Underlying Phenotypic Heterogeneity in Simplex Autism Spectrum Disorders

    Mechanisms Underlying Phenotypic Heterogeneity in Simplex Autism Spectrum Disorders Andrew H. Chiang Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2021 © 2021 Andrew H. Chiang All Rights Reserved Abstract Mechanisms Underlying Phenotypic Heterogeneity in Simplex Autism Spectrum Disorders Andrew H. Chiang Autism spectrum disorders (ASD) are a group of related neurodevelopmental diseases displaying significant genetic and phenotypic heterogeneity. Despite recent progress in ASD genetics, the nature of phenotypic heterogeneity across probands is not well understood. Notably, likely gene- disrupting (LGD) de novo mutations affecting the same gene often result in substantially different ASD phenotypes. We find that truncating mutations in a gene can result in a range of relatively mild decreases (15-30%) in gene expression due to nonsense-mediated decay (NMD), and show that more severe autism phenotypes are associated with greater decreases in expression. We also find that each gene with recurrent ASD mutations can be described by a parameter, phenotype dosage sensitivity (PDS), which characteriZes the relationship between changes in a gene’s dosage and changes in a given phenotype. Using simple linear models, we show that changes in gene dosage account for a substantial fraction of phenotypic variability in ASD. We further observe that LGD mutations affecting the same exon frequently lead to strikingly similar phenotypes in unrelated ASD probands. These patterns are observed for two independent proband cohorts and multiple important ASD-associated phenotypes. The observed phenotypic similarities are likely mediated by similar changes in gene dosage and similar perturbations to the relative expression of splicing isoforms.
  • Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C 'S Role in Working Memory

    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C 'S Role in Working Memory

    Neuropsychopharmacology (2017) 42, 2612–2622 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C 's Role in Working Memory 1 1 2 3 4,5 3 Donna Cosgrove , Omar Mothersill , Kimberley Kendall , Bettina Konte , Denise Harold , Ina Giegling , 3 6 6 7 Annette Hartmann , Alex Richards , Kiran Mantripragada , The Wellcome Trust Case Control Consortium , Michael J Owen6, Michael C O’Donovan6, Michael Gill4, Dan Rujescu3, James Walters2, Aiden Corvin4, Derek W Morris1 and Gary Donohoe*,1 1 The Cognitive Genetics & Cognitive Therapy Group, The School of Psychology and Discipline of Biochemistry, The Centre for Neuroimaging & Cognitive Genomics, National University of Ireland Galway, Galway, Ireland; 2Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK; 3Department of Psychiatry, Psychotherapy and Psychosomatics, Martin-Luther-University Halle-Wittenberg, Halle, Germany; 4 Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland; 5 6 School of Biotechnology, Dublin City University, Dublin, Ireland; MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK With 4100 common variants associated with schizophrenia risk, establishing their biological significance is a priority. We sought to establish cognitive effects of
  • 8P23.2-Pter Microdeletions: Seven New Cases Narrowing the Candidate Region and Review of the Literature

    8P23.2-Pter Microdeletions: Seven New Cases Narrowing the Candidate Region and Review of the Literature

    G C A T T A C G G C A T genes Article 8p23.2-pter Microdeletions: Seven New Cases Narrowing the Candidate Region and Review of the Literature Ilaria Catusi 1,* , Maria Garzo 1 , Anna Paola Capra 2 , Silvana Briuglia 2 , Chiara Baldo 3 , Maria Paola Canevini 4 , Rachele Cantone 5, Flaviana Elia 6, Francesca Forzano 7, Ornella Galesi 8, Enrico Grosso 5, Michela Malacarne 3, Angela Peron 4,9,10 , Corrado Romano 11 , Monica Saccani 4 , Lidia Larizza 1 and Maria Paola Recalcati 1 1 Istituto Auxologico Italiano, IRCCS, Laboratory of Medical Cytogenetics and Molecular Genetics, 20145 Milan, Italy; [email protected] (M.G.); [email protected] (L.L.); [email protected] (M.P.R.) 2 Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98100 Messina, Italy; [email protected] (A.P.C.); [email protected] (S.B.) 3 UOC Laboratorio di Genetica Umana, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy; [email protected] (C.B.); [email protected] (M.M.) 4 Child Neuropsychiatry Unit—Epilepsy Center, Department of Health Sciences, ASST Santi Paolo e Carlo, San Paolo Hospital, Università Degli Studi di Milano, 20142 Milan, Italy; [email protected] (M.P.C.); [email protected] (A.P.); [email protected] (M.S.) 5 Medical Genetics Unit, Città della Salute e della Scienza University Hospital, 10126 Turin, Italy; [email protected] (R.C.); [email protected] (E.G.) 6 Unit of Psychology, Oasi Research Institute-IRCCS,
  • Multivariate Analysis Reveals Genetic Associations of the Resting Default Mode Network in Psychotic Bipolar Disorder and Schizophrenia

    Multivariate Analysis Reveals Genetic Associations of the Resting Default Mode Network in Psychotic Bipolar Disorder and Schizophrenia

    Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia Shashwath A. Medaa,1, Gualberto Ruañob,c, Andreas Windemuthb, Kasey O’Neila, Clifton Berwisea, Sabra M. Dunna, Leah E. Boccaccioa, Balaji Narayanana, Mohan Kocherlab, Emma Sprootena, Matcheri S. Keshavand, Carol A. Tammingae, John A. Sweeneye, Brett A. Clementzf, Vince D. Calhoung,h,i, and Godfrey D. Pearlsona,h,j aOlin Neuropsychiatry Research Center, Institute of Living at Hartford Hospital, Hartford, CT 06102; bGenomas Inc., Hartford, CT 06102; cGenetics Research Center, Hartford Hospital, Hartford, CT 06102; dDepartment of Psychiatry, Beth Israel Deaconess Hospital, Harvard Medical School, Boston, MA 02215; eDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390; fDepartment of Psychology, University of Georgia, Athens, GA 30602; gThe Mind Research Network, Albuquerque, NM 87106; Departments of hPsychiatry and jNeurobiology, Yale University, New Haven, CT 06520; and iDepartment of Electrical and Computer Engineering, The University of New Mexico, Albuquerque, NM 87106 Edited by Robert Desimone, Massachusetts Institute of Technology, Cambridge, MA, and approved April 4, 2014 (received for review July 15, 2013) The brain’s default mode network (DMN) is highly heritable and is Although risk for psychotic illnesses is driven in small part by compromised in a variety of psychiatric disorders. However, ge- highly penetrant, often private mutations such as copy number netic control over the DMN in schizophrenia (SZ) and psychotic variants, substantial risk also is likely conferred by multiple genes bipolar disorder (PBP) is largely unknown. Study subjects (n = of small effect sizes interacting together (7). According to the 1,305) underwent a resting-state functional MRI scan and were “common disease common variant” (CDCV) model, one would analyzed by a two-stage approach.
  • Deregulation of CSMD1 Targeted by Microrna-10B Drives Gastric

    Deregulation of CSMD1 Targeted by Microrna-10B Drives Gastric

    Int. J. Biol. Sci. 2019, Vol. 15 2075 Ivyspring International Publisher International Journal of Biological Sciences 2019; 15(10): 2075-2086. doi: 10.7150/ijbs.23802 Research Paper Deregulation of CSMD1 targeted by microRNA-10b drives gastric cancer progression through the NF-κB pathway Xiang-Liu Chen1,2*, Lian-Lian Hong2*, Kai-Lai Wang2, Xiang Liu2, Jiu-Li Wang2, Lan Lei2, Zhi-Yuan Xu3, Xiang-Dong Cheng3 and Zhi-Qiang Ling1,2 1. Department of Digestive Oncology, the First Affiliated Hospital of Wenzhou Medical University; the First Provincial Wenzhou Hospital of Zhejiang, Wenzhou 325000. 2. Zhejiang Cancer Institute, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China. 3. Department of Digestive Oncology, Zhejiang Province Cancer Hospital, Zhejiang Cancer Center, Hangzhou 310022, China. *Contributed equally to this work. Corresponding author: Professor, Zhi-Qiang Ling, M.D., PhD. No.1 Banshan East Rd., Gongshu District, Hangzhou 310022, China. Telephone: +86-571-88122423; Fax: +86-571-88122423; Email: [email protected]; MSN: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2017.11.11; Accepted: 2019.06.05; Published: 2019.08.06 Abstract Aim: This study aimed to investigate the oncogenic activity of microRNA-10b by targeting CUB and sushi multiple domains protein 1 (CSMD1) in human gastric cancer (GC) and the underlying mechanisms.
  • Potential Impact of Mir-137 and Its Targets in Schizophrenia

    Potential Impact of Mir-137 and Its Targets in Schizophrenia

    Georgia State University ScholarWorks @ Georgia State University Psychology Faculty Publications Department of Psychology 4-2013 Potential Impact of miR-137 and Its Targets in Schizophrenia Carrie Wright University of New Mexico, [email protected] Jessica Turner Georgia State University, [email protected] Vince D. Calhoun University of New Mexico, [email protected] Nora I. Perrone-Bizzozero University of New Mexico, [email protected] Follow this and additional works at: https://scholarworks.gsu.edu/psych_facpub Part of the Psychology Commons Recommended Citation Wright C, Turner JA, Calhoun VD and Perrone-Bizzozero N (2013) Potential impact of miR-137 and its tar- gets in schizophrenia. Front. Genet. 4:58. doi: http://dx.doi.org/10.3389/fgene.2013.00058 This Article is brought to you for free and open access by the Department of Psychology at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Psychology Faculty Publications by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. HYPOTHESIS AND THEORY ARTICLE published: 26 April 2013 doi: 10.3389/fgene.2013.00058 Potential impact of miR-137 and its targets in schizophrenia Carrie Wright 1, Jessica A.Turner 2,3*,Vince D. Calhoun2,3 and Nora Perrone-Bizzozero1* 1 Department of Neurosciences, Health Sciences Center, University of New Mexico, Albuquerque, NM, USA 2 The Mind Research Network, Albuquerque, NM, USA 3 Psychology Department, University of New Mexico, Albuquerque, NM, USA Edited by: The significant impact of microRNAs (miRNAs) on disease pathology is becoming increas- Francis J. McMahon, National ingly evident.These small non-coding RNAs have the ability to post-transcriptionally silence Institute of Mental Health, USA the expression of thousands of genes.
  • Dysregulation of Post-Transcriptional Modification by Copy Number

    Dysregulation of Post-Transcriptional Modification by Copy Number

    Yoshikawa et al. Translational Psychiatry (2021) 11:331 https://doi.org/10.1038/s41398-021-01460-1 Translational Psychiatry ARTICLE Open Access Dysregulation of post-transcriptional modification by copy number variable microRNAs in schizophrenia with enhanced glycation stress Akane Yoshikawa1,2,ItaruKushima 3,4, Mitsuhiro Miyashita 1,5,6,KazuyaToriumi 1, Kazuhiro Suzuki 1,5, Yasue Horiuchi 1, Hideya Kawaji 7, Shunya Takizawa8,NorioOzaki 3, Masanari Itokawa1 and Makoto Arai 1 Abstract Previously, we identified a subpopulation of schizophrenia (SCZ) showing increased levels of plasma pentosidine, a marker of glycation and oxidative stress. However, its causative genetic factors remain largely unknown. Recently, it has been suggested that dysregulated posttranslational modification by copy number variable microRNAs (CNV-miRNAs) may contribute to the etiology of SCZ. Here, an integrative genome-wide CNV-miRNA analysis was performed to investigate the etiology of SCZ with accumulated plasma pentosidine (PEN-SCZ). The number of CNV-miRNAs and the gene ontology (GO) in the context of miRNAs within CNVs were compared between PEN-SCZ and non-PEN-SCZ groups. Gene set enrichment analysis of miRNA target genes was further performed to evaluate the pathways affected in PEN-SCZ. We show that miRNAs were significantly enriched within CNVs in the PEN-SCZ versus non-PEN-SCZ groups (p = 0.032). Of note, as per GO analysis, the dysregulated neurodevelopmental events in the two groups may have different origins. Additionally, gene set enrichment analysis of miRNA target genes revealed that miRNAs involved in glycation/oxidative stress and synaptic neurotransmission, especially glutamate/GABA receptor signaling, fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; were possibly affected in PEN-SCZ.
  • HBV Genome-Enriched Single Cell Sequencing Revealed Heterogeneity in HBV-Driven HCC

    HBV Genome-Enriched Single Cell Sequencing Revealed Heterogeneity in HBV-Driven HCC

    HBV Genome-Enriched Single Cell Sequencing Revealed Heterogeneity in HBV-Driven HCC Wenhui Wang Icahn School of Medicine at Mount Sinai Yan Chen Huazhong University of Science and Technology Tongji Hospital Hepatic Surgery Center Liang Wu Beijing Genomics Institute: BGI Group Yi Zhang Hebei University of Science and Technology Seungyeul Yoo Icahn School of Medicine at Mount Sinai Quan Chen Icahn School of Medicine at Mount Sinai Shiping Liu Beijing Genomics Institute: BGI Group Yong Hou Huazhong University of Science and Technology Tongji Hospital Hepatic Surgery Center Xiao-ping Chen Huazhong University of Science and Technology Tongji Hospital Hepatic Surgery Center Qian Chen Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology Jun Zhu ( [email protected] ) Icahn School of Medicine at Mount Sinai https://orcid.org/0000-0003-0834-8178 Research article Keywords: Hepatocellular Carcinoma, Hepatitis B virus integration, Enriched single cell sequencing, Copy number variation, Clonal evolution. Posted Date: May 19th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-537064/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License HBV Genome-Enriched Single Cell Sequencing Revealed Heterogeneity in HBV-Driven HCC Wenhui Wang1,2†, Yan Chen3†, Liang Wu4, Yi Zhang5, Seungyeul Yoo1,2,6, Quan Chen1,2,6, Shiping Liu4, Yong Hou4, Xiao-ping Chen3, Qian Chen7*, Jun Zhu1,2,6,8*, 1Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
  • View See [1] and [2])

    View See [1] and [2])

    BMC Bioinformatics BioMed Central Proceedings Open Access EasyCluster: a fast and efficient gene-oriented clustering tool for large-scale transcriptome data Ernesto Picardi*1, Flavio Mignone2 and Graziano Pesole*1,3 Address: 1Dipartimento di Biochimica e Biologia Molecolare "E. Quagliariello", Università degli Studi di Bari, 70126 Bari, Italy, 2Dipartimento di Chimica Strutturale e Stereochimica Inorganica, Università degli Studi di Milano, 20133 Milano, Italy and 3Istituto Tecnologie Biomediche del Consiglio Nazionale delle Ricerche, via Amendola 122/D, 70125 Bari, Italy Email: Ernesto Picardi* - [email protected]; Flavio Mignone - [email protected]; Graziano Pesole* - [email protected] * Corresponding authors from European Molecular Biology Network (EMBnet) Conference 2008: 20th Anniversary Celebration Martina Franca, Italy. 18–20 September 2008 Published: 16 June 2009 BMC Bioinformatics 2009, 10(Suppl 6):S10 doi:10.1186/1471-2105-10-S6-S10 <supplement> <title> <p>European Molecular Biology Network (EMBnet) Conference 2008: 20th Anniversary Celebration. Leading applications and technologies in bioinformatics</p> </title> <editor>Erik Bongcam-Rudloff, Domenica D'Elia, Andreas Gisel, Sophia Kossida, Kimmo Mattila and Lubos Klucar</editor> <note>Proceedings</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S6-info.pdf</url> </supplement> This article is available from: http://www.biomedcentral.com/1471-2105/10/S6/S10 © 2009 Picardi et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: ESTs and full-length cDNAs represent an invaluable source of evidence for inferring reliable gene structures and discovering potential alternative splicing events.